Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients

Leukemia
R O CasasnovasE Solary

Abstract

This study prospectively analysed the relationships between immunophenotypic and cytogenetic features of blast cells in 432 acute non-lymphoblastic leukemias (ANLL) at presentation. An abnormal karyotype was detected in 232 cases (54%). These abnormalities were related to immunophenotypic markers as detected using a consensual panel of monoclonal antibodies allowing lineage assignment and investigation of myeloid marker expression on blast cells. In univariate analysis, CD9, CD10, CD15, CD34 and TdT expression appeared significantly associated with chromosomal anomalies. Multivariate analysis identified CD34 and CD9 expression as independently predictive of the presence of at least one cytogenetic abnormality (P < 10(-4) and P < 0.03, respectively). Significant associations between immunophenotypic and karyotypic features were observed both within individual FAB subgroups and independently from morphological criteria. Specific features were seen in five ANLL entities: M0 or M1/B lineage antigen positivity/t(9;22) or del(11)(q23); M2/CD13-/t(8;21); M4/CD13+, CD34+, CD36+/inv(16); M4 or M5/lack of B lineage antigen/del(11)(q23) or t(9;11). More practically, and although the relationships demonstrated only represent a fraction of ...Continue Reading

Citations

Aug 5, 2003·Current Oncology Reports·María-Belén VidrialesJesús F San-Miguel
Feb 25, 2000·Cancer Genetics and Cytogenetics·P E CrossenM J Morrison
Jan 14, 2000·Critical Reviews in Oncology/hematology·J F San MiguelJ J van Dongen
Sep 13, 2001·Clinical and Laboratory Haematology·M HurH I Cho
Dec 29, 2007·The American Journal of Surgical Pathology·Francisco VegaLynne V Abruzzo
Sep 26, 2012·The Cancer Journal·Julie M Vose
Sep 15, 2004·American Journal of Clinical Pathology·Mauricio P OyarzoL Jeffrey Medeiros
Mar 26, 2005·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·Yimin Ge, M Tarek Elghetany
Jul 8, 2008·Leukemia & Lymphoma·Asa Rangert DerolfAnna Porwit
Sep 29, 2009·Leukemia Research·Bruno C MedeirosAsh A Alizadeh
Oct 9, 2003·British Journal of Haematology·Birgitte S PreissUNKNOWN AML Study Group Region of Southern Denmark
Dec 7, 2007·Cytometry. Part B, Clinical Cytometry·Jine ZhengShiang Huang
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Wu-Lin Shan, Xiao-Ling Ma
May 4, 2002·Best Practice & Research. Clinical Haematology·Jesús F San-MiguelAlberto Orfão
Jul 3, 2002·Leukemia·O Hrusák, A Porwit-MacDonald
Aug 8, 2018·Molecular Cancer Therapeutics·Abhishek AsthanaReshmi Parameswaran

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.